Vyndaqel Archives -

Pfizer reckons it will make a whopping $22 billion in sales of its oral COVID-19 antiviral Paxlovid in

Pfizer’s COVID boom goes on, as it eyes $22bn in Paxlovid sales this year

https://pharmaphorum.com/news/pfizers-covid-boom-goes-on-as-it-eyes-22bn-in-paxlovid-sales-this-year/

AstraZeneca has clearly made the rare disease transthyretin amyloidosis (ATTR) a key component of its rare disease pipeline,

AstraZeneca goes bigger in amyloidosis with Neurimmune deal

https://pharmaphorum.com/news/astrazeneca-goes-bigger-in-amyloidosis-with-neurimmune-deal/

NICE has rejected regular NHS funding for Pfizer’s Vyndaqel (tafamidis) for a rare heart condition, although it has

NICE says ‘no’ to Pfizer’s Vyndaqel for rare heart condition

https://pharmaphorum.com/news/nice-says-no-to-pfizers-vyndaqel-for-rare-heart-condition/

Pfizer’s Vyndaqel has become the first drug to be approved for transthyretin amyloidosis with cardiomyopathy (ATTR-CM) in Europe,

Pfizer’s EU Vyndaqel okay ‘sets up $1.5bn sales next year’

https://pharmaphorum.com/news/pfizers-eu-vyndaqel-okay-sets-up-1-5bn-sales-next-year/

Vyndaqel